Are Pharma Companies Data Fiduciaries Under DPDP Act?

Are pharma companies data fiduciaries under DPDP Act?

Yes. In most cases, pharma companies qualify as data fiduciaries under the DPDP Act because they decide why and how doctor, patient, or HCP data is collected, used, stored, shared, and activated across marketing, medical, commercial, and digital workflows.

What Does Data Fiduciary Mean Under DPDP Act?

Under the DPDP Act, a data fiduciary is the entity that determines why and how personal data is processed.

A data fiduciary is the organisation that decides the purpose and method of personal data processing.

This definition is intentionally broad. It focuses on decision-making power rather than technical execution. The entity that decides the purpose of data use and the means of processing is the one held accountable.

This connects closely with the concept of the data principal, because consent must come from the individual whose data is being processed.

In pharma organisations, these decisions are typically made by internal teams. Marketing decides which doctors to target. Medical teams decide what content is shared. Commercial teams define engagement strategies. Technology teams select platforms and tools.

Even when execution is outsourced, the underlying decisions originate within the pharma company.

Why Pharma Companies Usually Qualify as Data Fiduciaries?

Pharma companies control the core elements that define data fiduciary status.

Pharma companies usually act as data fiduciaries because they decide:

• which doctors or patients to target

• what data is collected

• which campaigns are executed

• which channels are used

• how long data is retained

• which vendors get access

• how CRM and AI tools use the data

They decide which personal data is collected, whether it relates to doctors, patients, or other healthcare professionals. They define the purpose of data use, such as marketing communication, medical education, or engagement analytics. They choose the channels through which communication occurs. They determine how long data is retained and when it is deleted.

Vendors and agencies may process data on behalf of pharma companies, but they do not typically decide the purpose or scope of processing independently.

This places pharma companies firmly in the role of data fiduciary under DPDP.

Common Misconception: Agencies as Data Fiduciaries

A frequent misconception in pharma marketing is that agencies or platform providers act as data fiduciaries because they operate the tools and run the campaigns.

DPDP draws a clear distinction between data fiduciaries and data processors. Data processors act on instructions provided by the data fiduciary. They do not define the purpose of processing.

In most pharma marketing arrangements, agencies follow briefs, campaign plans, and data access rules defined by the pharma company. This makes them data processors, not data fiduciaries.

The responsibility for compliance remains with the pharma company.

How Data Fiduciary Status Affects Pharma Marketing Teams

Being classified as a data fiduciary has practical consequences for marketing and commercial teams.

Example:

If a pharma company runs a WhatsApp campaign to doctors using data sourced from a vendor, the pharma company must still prove that the data was collected lawfully, consent was valid, and the campaign purpose matched the consent.

Marketing teams must ensure that data used in campaigns is collected lawfully and with valid consent. They must ensure that data is used only for the purposes communicated to doctors. They must be able to demonstrate compliance during audits or investigations.

This is why understanding explicit consent versus traditional opt-in is critical under DPDP.

This shifts compliance from being a background legal concern to an operational responsibility embedded in daily workflows.

Data Fiduciary Responsibilities in Doctor Engagement

Doctor engagement relies heavily on personal data. Contact details, engagement history, preferences, and digital interaction data all qualify as personal data under DPDP.

This makes doctor data compliance under DPDP a core marketing, CRM, and commercial operations issue—not only a legal concern.

As data fiduciaries, pharma companies must ensure that this data is accurate, up to date, and used appropriately. They must respect consent withdrawal and provide mechanisms for doctors to exercise their data rights.

Consent withdrawal must also cascade across systems when a doctor changes permission.

This directly affects how doctor databases are managed and how engagement programs are designed.

Impact on CRM Systems and Marketing Platforms

This is where fiduciary responsibility becomes a technology problem.

CRM systems play a central role in doctor engagement. However, many CRMs were designed for sales enablement rather than regulatory accountability.

Under DPDP, data fiduciaries must ensure that CRMs support consent tracking, purpose mapping, and enforcement at the point of execution. A CRM that allows outreach without validating consent introduces compliance risk.

Many pharma CRMs fail because they store consent but do not enforce it at execution.

This is why DPDP-compliant HCP marketing architectures are becoming critical for pharma organisations. They connect data fiduciary responsibilities directly with marketing execution systems.

If your CRM cannot validate consent by purpose, channel, and doctor profile before outreach, your organisation may be exposed under DPDP. A consent-first HCP marketing architecture helps close this gap before campaigns go live.

Vendor Management Under Data Fiduciary Obligations

Being a data fiduciary also affects how pharma companies work with vendors.

Contracts must clearly define roles and responsibilities. Data access must be limited to what is necessary. Vendors must follow documented instructions. Audit rights and safeguards must be in place.

Pharma companies cannot rely on vendor assurances alone. They must actively govern how personal data is handled across the ecosystem.

Vendor governance checklist for pharma data fiduciaries:
• define processor role in contract
• restrict data access
• document processing instructions
• include audit rights
• enforce consent withdrawal
• prevent unauthorised data reuse
• monitor vendor compliance

Data Fiduciary Role in AI Driven Marketing

AI driven marketing introduces additional complexity.

AI increases fiduciary risk because data may move from direct outreach into prediction, profiling, segmentation, and automated recommendations. Each of these uses must remain aligned with consent and purpose.

AI systems often rely on large datasets and behavioural signals. As data fiduciaries, pharma companies must ensure that AI models are trained on lawfully collected data and that outputs respect consent scope and purpose limitation.

Consent withdrawal must propagate across AI systems, not remain confined to source databases. This is part of real-time consent enforcement at the point of engagement.
This requires closer integration between data governance and AI deployment.

What Happens When Pharma Companies Ignore Fiduciary Status?

Ignoring data fiduciary responsibilities does not eliminate liability. It increases risk.

If a violation occurs, regulators will look at who decided why the data was used. In most cases, this points back to the pharma company, not the vendor.

This can lead to penalties, audits, and reputational damage. It can also disrupt marketing operations if data usage is restricted suddenly.

Preparing Pharma Teams for Data Fiduciary Accountability

The most effective response to DPDP is proactive preparation — not last-minute compliance scrambling.
Pharma companies need to document data purposes, consent mechanisms, and processing workflows clearly. Marketing teams must understand their fiduciary responsibilities — not just in policy, but in day-to-day decisions. Systems must be evaluated for real consent-enforcement capability, not paper compliance.
Treat data fiduciary accountability as a design principle, not an afterthought. The companies that build it in early will move faster when enforcement tightens. The ones that retrofit will spend the next two years cleaning up.

How pharma companies should prepare:

• Map every doctor and patient data flow across CRM, marketing automation, medical affairs, and field systems.
• Define a specific, lawful purpose for each data use case — and document it.
• Review consent-capture mechanisms across email, WhatsApp, in-person, and digital ads.
• Check whether your CRM can actually enforce consent at the point of outreach, not just record it.
• Audit vendor access, data-sharing contracts, and third-party processor agreements.
• Build consent-withdrawal workflows that respond within statutory timelines and leave a clean audit trail.
• Train marketing, medical, IT, and agency teams on what changes in their day-to-day for DPDP.
• Maintain audit-ready documentation that holds up under regulator scrutiny.

Why Data Fiduciary Status Is Not Optional?

Under DPDP, data fiduciary status is not something a company can opt into or out of. It is determined by how data decisions are made in practice.

For pharma companies, the conclusion is clear. If you decide how doctor or patient data is used, you are a data fiduciary.

Accepting this reality is the first step toward compliant and sustainable marketing operations.

Closing Perspective and CTA

The DPDP Act makes one thing clear. Control over data decisions brings accountability.

For pharma companies, data fiduciary status is not a legal technicality. It is a practical reality that shapes how doctor engagement, marketing execution, and digital transformation must operate.

If you are evaluating how to meet data fiduciary responsibilities while running DPDP-compliant HCP marketing, this page explains how consent-first, accountable engagement models are being implemented in real pharma environments.

Frequently Asked Questions on Data Fiduciary Status in Pharma